Provectus' Oral PV-10 Shows Strong Anti-Tumor Activity in Preclinical Bladder Cancer Study, Yielding Tumor-Free Survivors
PVCT sits 82% above its 52-week low of $0.038 on light trading volume (0.2× avg).
Summary
Provectus Biopharmaceuticals announced positive preclinical results for its drug candidate PV-10 in an orthotopic bladder carcinoma tumor xenograft model. Oral PV-10 monotherapy was the top-ranked treatment arm, demonstrating significant anti-tumor activity and leading to long-term survivors who showed an absence of gross bladder tumor at the study's end. This positive pipeline development provides a much-needed boost following the company's recent 10-Q filing on May 14, which highlighted a worsening financial position and a going concern warning. For a micro-cap biotech, strong preclinical data like this is material, offering validation for its proprietary technology and potentially attracting investor interest. Traders will now monitor for updates on PV-10's clinical development path and any related financing activities.
At the time of this announcement, PVCT was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $29.1M. The 52-week trading range was $0.04 to $0.11. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.